RECRUITING

Pan Tumor Rollover Study

Talk to us

Conditions

CancerRolloverpan-tumor

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Main Objective of this study is to examine long-term safety of nivolumab monotherapy including combinations and other cancer therapies in various tumor types.

Official Title

Pan-Tumor Study for Long-term Treatment of Cancer Patients Who Have Participated in BMS Sponsored Trials Investigating Nivolumab and Other Cancer Therapies

Quick Facts

Study Start:2019-08-09
Study Completion:2029-08-25
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT03899155

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Signed Written Informed Consent.
  2. * Eligible to receive continued study treatment per the Parent Study, including treatment beyond progression per investigator assessment in the Parent Study.
  3. * On treatment hold in the Parent Study following long-lasting response or are eligible for treatment rechallenge as defined in the Parent Study.
  4. * WOCBP and male participants who are sexually active must agree to follow instructions for method(s) of contraception as described below and included in the ICF.
  1. * Participant is not eligible for study treatment per the Parent Study eligibility criteria.
  2. * Participants not receiving clinical benefit as assessed by the Investigator.
  3. * Any clinical adverse event (AE), laboratory abnormality, or intercurrent illness which, in the opinion of the Investigator, indicates that participation in the study is not in the best interest of the participant.
  4. * Other protocol-defined Inclusion/Exclusion Criteria apply

Contacts and Locations

Study Contact

BMS Study Connect Contact http://www.bmsstudyconnect.com/
CONTACT
855-907-3286
Clinical.Trials@bms.com
First line of the email MUST contain NCT# and Site#
CONTACT

Principal Investigator

Bristol-Myers Squibb
STUDY_DIRECTOR
Bristol-Myers Squibb

Study Locations (Sites)

University of Arizona College of Medicine
Tucson, Arizona, 85724
United States
Innovative Clinical Research Institute
Lynwood, California, 90262
United States
Local Institution
San Francisco, California, 94115
United States
UCSF Medical Center - Helen Diller Family Comprehensive Cancer Center - Melanoma Center
San Francisco, California, 94143
United States
University of Colorado
Aurora, Colorado, 80045
United States
Local Institution - 0095
New Haven, Connecticut, 06520
United States
Georgetown-Lombardi Comprehensive Cancer Center
Washington, District of Columbia, 20007-2113
United States
Florida Cancer Affiliates
Ocala, Florida, 34474
United States
Local Institution
Orlando, Florida, 32806
United States
H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc.
Tampa, Florida, 33612
United States
Local Institution - 0105
Chicago, Illinois, 60637
United States
Local Institution
Maywood, Illinois, 60153
United States
Advocate Medical Group - Park Ridge - Luther Ln - Oncology
Park Ridge, Illinois, 60068
United States
University of Kansas Cancer Center
Westwood, Kansas, 66205
United States
Cancer Center of Kansas
Wichita, Kansas, 67214-3728
United States
University of Louisville-James Graham Brown Cancer Center
Louisville, Kentucky, 40202
United States
Johns Hopkins
Baltimore, Maryland, 21287
United States
Massachusetts General Hospital
Boston, Massachusetts, 02114
United States
Dana_Farber Cancer Institute (DFCI)
Boston, Massachusetts, 02215
United States
Local Institution - 0081
Boston, Massachusetts, 02215
United States
University of Michigan Rogel Comprehensive Cancer Center UMCCC
Ann Arbor, Michigan, 48109
United States
Allina Health
Minneapolis, Minnesota, 55407-3723
United States
Local Institution
Saint Louis, Missouri, 63110
United States
Local Institution - 0205
Omaha, Nebraska, 68130
United States
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire, 03756
United States
Local Institution
Albuquerque, New Mexico, 87131
United States
Roswell Park Cancer Institute
Buffalo, New York, 14263
United States
Local Institution
New York, New York, 10016
United States
Local Institution
New York, New York, 10065
United States
Weill Cornell Medical College
New York, New York, 10065
United States
Weill Cornell Medical College
New York, New York, 10065
United States
Levine Cancer Center
Charlotte, North Carolina, 28204
United States
Duke University
Durham, North Carolina, 27705
United States
Oncology Hematology Care
Cincinnati, Ohio, 45242
United States
Local Institution
Cleveland, Ohio, 44106
United States
The Ohio University
Columbus, Ohio, 43210
United States
Local Institution - 0246
Tulsa, Oklahoma, 74146
United States
Lehigh Valley Hospital
Allentown, Pennsylvania, 18103
United States
St. Lukes University Health Network
Easton, Pennsylvania, 18045
United States
Allegheny Valley Hospital
Natrona Heights, Pennsylvania, 15065
United States
Local Institution
Philadelphia, Pennsylvania, 19104
United States
Local Institution - 0162
Philadelphia, Pennsylvania, 19111
United States
Local Institution - 0110
Pittsburgh, Pennsylvania, 15213
United States
Charleston Oncology
Charleston, South Carolina, 29414
United States
Local Institution
Greenville, South Carolina, 29615
United States
Local Institution
Chattanooga, Tennessee, 37404
United States
Tennesse Oncology
Nashville, Tennessee, 37203
United States
Vanderbilt University Medical Center
Nashville, Tennessee, 37232
United States
Local Institution
Dallas, Texas, 75390
United States
Local Institution - 0364
Houston, Texas, 77030-4000
United States
Huntsman Cancer Institute
Salt Lake City, Utah, 84112-5550
United States
Local Institution
Charlottesville, Virginia, 22908
United States
Public Hospital of King County District 1 Valley Medical Center
Renton, Washington, 98055
United States
Local Institution
Madison, Wisconsin, 53792
United States
UW Health - UW Carbone Cancer Center - Medical Oncology Clinic
Madison, Wisconsin, 53792
United States

Collaborators and Investigators

Sponsor: Bristol-Myers Squibb

  • Bristol-Myers Squibb, STUDY_DIRECTOR, Bristol-Myers Squibb

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2019-08-09
Study Completion Date2029-08-25

Study Record Updates

Study Start Date2019-08-09
Study Completion Date2029-08-25

Terms related to this study

Keywords Provided by Researchers

  • Rollover
  • pan-tumor

Additional Relevant MeSH Terms

  • Cancer